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CASE PRESENTATION
An 18-year-old white male was admitted to the hospital for a lung
transplant. This high school senior has no family history of lung disease
and currently lives at home.
The patient had had seizures on day 2 after birth and has moderate
cerebral palsy and well-controlled asthma. He was well until approxi-
mately one year prior to admission, when he fainted while lifting weights.
Dyspnea, weakness, and light-headedness developed over the next three
months. Primary pulmonary hypertension, diagnosed approximately seven
months prior to this admission, worsened rapidly approximately two
months later. The patient successfully underwent lung transplantation.
After the transplant, he received glucocorticoids, cyclosporine, and
approximately 50–75 g/day of amino acids. He had been mildly hypergly-
cemic. On postoperative day 14, he received an additional 1 g of
methylprednisolone for presumed transplant rejection. He received no
blood transfusion. From days 3 through 11, the BUN and serum creatinine
concentrations increased in parallel, from 22 mg/dl and 1.1 mg/dl to 123
mg/dl and 3.2 mg/dl, respectively. Thereafter, the cyclosporine level was
reduced, and the serum creatinine declined somewhat. The BUN contin-
ued to rise, however. The serum sodium concentration decreased from 140
mEq/liter to 129 mEq/liter between day 3 and day 9, then increased
gradually to 150 mEq/liter on day 15. Urine output ranged from 1 to 4
liters/day, but was fixed around 2 liters/day from days 9 through 14. Serial
determinations of body weight were made on different scales and corre-
lated poorly with intake and output (Table 1). Azotemia prompted a
nephrology consultation on postoperative day 15.
On examination, the patient was awake and alert. Although intubated,
he complained of thirst. The blood pressure was 103/64 mmHg; heart rate,
114 beats/min; the heart was in sinus rhythm; and the central venous
pressure was 6 cm. Oxygen saturation was 96%. The skin and mucous
membranes were dry. No edema was present. He had no signs of
gastrointestinal bleeding.
Table 1 displays the pertinent clinical and laboratory values for this
patient. In addition, the serum albumin was 2.4 g/dl. A 2 liter, 24-hour
urine collection contained 30 g of urea nitrogen and 14 mEq/liter of
chloride. The urine osmolarity on another spot sample was 650 mOsm/kg.
The plasma osmolality was 360 mOsm/kg. The fractional excretion of urea
was approximately 25%. Based on the rate of rise of the BUN and the
amount of urea being excreted, the protein catabolic rate was estimated to
be approximately 200 g/day.
On the basis of the physical exam, the patient was thought to be volume
depleted. The high urine osmolarity and low fractional excretion of urea
indicated the presence of endogenous ADH. The rising serum sodium
suggested the loss of electrolyte-free water. The urine urea content
indicated that despite the low fractional excretion of urea, 75% of the total
urine output (1.5 liters/day) was obligated to the excretion of urea. All
other things being equal (even the patient’s inability to concentrate the
urine above 650 mOsm/kg), if the protein catabolic rate were reduced to
60 g/day and the patient were placed in zero nitrogen balance, the urine
output would have decreased to 875 ml/day. If the decrease in excretory
burden and cessation of diuretics would allow for more efficient concen-
tration of the urine, then the volume would decrease further. The
consulting nephrologist recommended that the patient be given hypotonic
saline to restore effective extracellular volume and to facilitate excretion
of urea. This fluid infusion promptly reduced both the BUN and serum
creatinine and corrected the hypernatremia.
DISCUSSION
DR. ROLAND C. BLANTZ (Professor of Medicine and Head,
Division of Nephrology, Hypertension and Bioengineering Institute,
University of California, and Veterans Affairs Medical Center, San
Diego, California, USA): This case is characterized by a progres-
sive elevation in BUN concurrent with a more modest increase in
serum creatinine concentration and a tendency to both hyper-
natremia and hyperosmolarity. When first seen by the nephrolo-
gist, the patient appeared to be volume depleted; this impression
was supported by the physical findings and laboratory data.
The clinical syndrome of pre-renal or functional renal failure is
characterized by intact renal parenchymal function but renal
hypoperfusion and typically is accompanied by a high ratio of
BUN to serum creatinine and a low urine volume. These features
arise as consequences of elevated levels of antidiuretic hormone
(ADH), which increase reabsorption of both water and urea [1].
The present case is an instance of pre-renal failure that deviates
from this paradigm because the urine volume was not low.
Homer Smith demonstrated 40 years ago that urea clearance is
not a constant function of glomerular filtration rate (GFR) [2].
Urea back-diffuses into the papillary interstitium under the
influence of antidiuretic hormone. The fraction of the tubular
content that back-diffuses varies inversely with flow in the collect-
ing duct. In the absence of ADH and in the presence of high urine
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flow, urea clearance approaches 80% of the GFR [3]. In the
presence of ADH, urea clearance can fall to 25% of the GFR.
This young man with pre-renal failure presented diagnostic
difficulty to the attending physicians because his urine volume was
not low. Measurement of the urine osmolarity and concentrations
of the main urinary solutes, however, indicated that ADH must
have been present and that his renal tubular function was basically
intact. Furthermore, it was evident that the BUN had increased
because of both an excessive protein catabolic rate and increased
tubular urea reabsorption. A rise in plasma ADH levels is
mediated both by hypovolemia and by increased extracellular
osmolality. Hypovolemia might not have been the only factor
driving ADH in this patient. The osmotic and volume stimuli to
ADH were exacerbated by the obligate loss of electrolyte-free
water required to excrete 30 g/day of urea nitrogen. The loss of
“free water” necessitated by urea excretion in turn also increased
plasma osmolality and led to further increases in ADH. This
obligate water loss created a positive feedback cycle for urea
retention in which increased urea production, via effects on
systemic volume and sodium concentration, impaired urea excre-
tion. The mechanisms that reduced the GFR in this patient are
more complex and will be addressed later, but reduced GFR per
se also decreases tubular flow rate and increases urea back-
diffusion. This positive-feedback cycle was broken, and the patient
improved with the administration of hypotonic saline, which
restored volume and reduced serum osmolarity. Pre-renal
azotemia was suggested by the fact that treatment not only
facilitated urea excretion and decreased the BUN but also re-
duced the serum creatinine.
Most cases of pre-renal azotemia present little diagnostic
challenge, but the condition can go unrecognized when the urine
output is high. In a series of patients with polyuric pre-renal
failure, renal concentrating defects caused excessive water excre-
tion with relative NaCl retention secondary to volume losses [4].
Hypernatremia due to the loss of electrolyte-free water is an early
clue to the presence of a polyuric pre-renal state. The current
patient excreted an excessive amount of water because his illness
generated an excessive amount of urea. The syndrome of volume
depletion and non-oliguric pre-renal failure associated with large
solute loads is not uncommon in our experience; it occurs most
often in the surgical ICU and in burn and trauma units. Patients
with extensive burns are given as much as 2 g/kg of amino acids
per day and generate considerable quantities of urea. Glucose and
mannitol also commonly produce polyuric pre-renal failure, al-
though hypernatremia is less pronounced in these instances
because the osmotic effect of these solutes draws water into the
extracellular space [5, 6]. This property is not shared by urea,
which easily crosses cell membranes. Mannitol is occasionally
prescribed for neurosurgical patients with elevated intracranial
pressure after head trauma; in this situation, serum potassium can
increase transiently after bolus mannitol administration because
of solvent drag and shifts of water from the intracellular compart-
ment. Hypokalemia can follow because of urinary potassium
losses [5].
Mechanisms of pre-renal failure
Pre-renal or functional renal failure usually arises as a physio-
logic response to reduced “effective” extracellular volume, de-
fined by decreased volume receptor stimulation and increased
adrenergic activity, and can accompany actual volume loss, con-
gestive heart failure, cirrhosis, nephrosis, or sepsis (Fig. 1). The
primary defense against effective volume depletion occurs at the
level of tubular reabsorption. These initial compensatory defenses
involve increased adrenergic and angiotensin II activity as well as
increased aldosterone influence on the tubule; the net effect is
increased proximal and distal tubular reabsorption. The subse-
quent reduction in GFR, required by the definition of renal
“failure,” arises when this primary defense is inadequate and is
mediated, in large part, by further activation of the same neuro-
humoral systems that modulate tubular reabsorption. This sec-
ondary reduction in GFR might be considered the stage of renal
decompensation. Badr and Ichikawa have provided an excellent
summary of the neurohumoral systems underlying the renal
responses in these clinical conditions [7]. These systems include
Table 1. Patient’s clinical and laboratory data
POD
Na
mEq/liter
Weight
kg
Urine output
cc/24 hrs
Hct
%
Glucose BUN Creat
CsAa
ng/mlmg/dl
1 145 — 1635 40.0 224 18 1.1 218
2 139 72.5 1985 38.9 156 19 1.3 484
3 140 72.9 3945 35.2 — 22 1.1 786
4 137 70.4 3595 35.0 — 36 1.6 798
5 136 68.9 2935 36.2 141 59 2.0 621
6 136 68.0 2130 35.0 — 64 2.1 741
7 135 66.4 900 33.8 — 60 2.1 521
8 132 70.2 1450 32.3 — 65 2.5 546
9 129 67.6 1930 32.5 206 79 3.0 445
10 133 69.5 2765 30.3 277 102 3.2 528
11 — 67.6 2050 33.6 — 123 3.3 454
12 139 62.5 2180 32.3 — 129 2.5 457
13 140 60.0 2160 29.5 — 129 2.1 247
14 145 65.1 1732 31.3 192 120 2.1 244
15a 150 64.9 2760 31.3 — 146 2.2 249
16 153 66.0 2366 30.9 — 154 2.0 —
25 147 70.0 1600 39.9 — 81 1.3 379
26 145 70.5 2280 36.0 — 59 1.1 343
Abbreviations are: CsA, cyclosporine; POD, postoperative day; Hct, hematocrit; BUN, blood urea nitrogen.
a A nephrology consultation was obtained on postoperative day 15.
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the renal sympathetic nerves, renin-angiotensin-aldosterone, and
ADH. Also, effective volume depletion can reduce GFR by
increasing the sensitivity of tubuloglomerular feedback.
Angiotensin II. Increased intrarenal AII activity is critical among
the systems contributing to the renal response to volume deple-
tion and congestive heart failure (Fig. 1). Angiotensin II increases
proximal tubular reabsorption, and AII receptor blockade reduces
absolute and fractional proximal reabsorption in chronic salt
depletion [8–10]. Angiotensin II exerts complex effects on glo-
merular ultrafiltration by increasing afferent and efferent arterio-
lar resistances, increasing the glomerular hydrostatic pressure
gradient (DP), and decreasing the glomerular ultrafiltration coef-
ficient (LpA or Kf) [8]. Increases in afferent and efferent arterio-
lar resistance also significantly reduce single-nephron plasma flow
rate. Thus a balance develops between positive influences (in-
creased DP) and negative influences (decreased plasma flow and
decreased LpA) that together produce a net effect on GFR. With
both modest volume depletion and congestive heart failure,
increased AII activity actually can preserve GFR because it causes
preferential constriction of the efferent arteriole. Efferent arte-
riolar vasoconstriction increases DP and results in a greater
filtration fraction. This increase tends to offset the effect on GFR
of reducing nephron plasma flow [9, 11]. With more severe
volume depletion or severe CHF, which leads to greater AII
activity, the afferent arterioles constrict and reduce both renal
plasma flow and filtration fraction [7]. Obviously, therapy directed
at restoration of GFR through blockade of angiotensin II activity
would not have been appropriate in today’s patient, given his
volume-depleted state.
The effects of AII in pre-renal states are counteracted by
endogenous intrarenal vasodilators, primarily prostaglandins [12,
13] and nitric oxide (NO) [14]. Although vasodilatory prostaglan-
dins and nitric oxide act as primary vasodilators in the systemic
circulation, in the kidney these substances primarily mediate their
influences by antagonizing the effects of vasoconstrictors such as
angiotensin II and renal adrenergic activity. The effects of inhib-
iting prostaglandin generation in pre-renal states are complex.
Acute inhibition of cyclo-oxygenase increases renal vasoconstric-
tion and further reduces GFR [7, 12, 13]. However, chronic
inhibition of cyclo-oxygenase reduces intrarenal AII generation
[15] and does not decrease GFR. Nitric oxide exerts equally
complex effects within the kidney. Although NO can exert tonic
influences as an antagonist of angiotensin II, NO also appears to
stimulate the renin-angiotensin system such that chronic reduc-
tions in NO activity can result in reduced intrarenal angiotensin II
generation [16, 17]. In the current patient, prior and concurrent
administration of cyclosporine might have suppressed the gener-
ation of prostaglandins and NO within the kidney [18], resulting in
a state of diminished AII activity within the glomerular microcir-
culation. This phenomenon has been reported in experimental
models of subacute cyclosporine toxicity [16, 17].
Renal adrenergic activity. The renal sympathetic nerves contrib-
ute significantly to the pre-renal failure encountered with either
volume deficits or congestive heart failure [19–21]. Angiotensin II
as well as adrenergic activity contribute to the increased renal
vascular resistance during chronic NaCl depletion (Fig. 1) [19]. In
this patient, cyclosporine might have further magnified these
effects by increasing volume depletion, by decreasing angiotensin
II influences within the kidney, and by magnifying renal adrener-
gic activity [16]. Acute renal denervation restores single-nephron
GFR (SNGFR) to normal levels in chronically NaCl-depleted rats
via reductions both in afferent and efferent arteriolar resistances;
as a result, nephron plasma flow increases [19]. If NaCl-depleted
rats are pretreated with AII receptor blockers, acute renal dener-
vation also improves SNGFR and nephron plasma flow, but only
via reductions in afferent arteriolar resistance [19]. These studies
suggest that in NaCl-depletion, adrenergic activity independently
constricts the afferent arteriole and that adrenergic activity influ-
ences efferent arteriolar resistance by modulating AII. When
renal nerves are stimulated directly, SNGFR decreases by approx-
imately 25% as a result of reductions in both DP and nephron
plasma flow. However, if AII receptor blockers are administered
prior to renal nerve stimulation, the reduction in SNGFR is
reduced to less than 10%. This effect could not be attributed to
impaired release of norepinephrine during renal nerve stimula-
tion [22].
Renal nerve activity is linked to renin release through b-adren-
ergic receptors on renin-containing cells. At another level, a2-
adrenergic influences, although purported to decrease renin se-
cretion, increase the activity of AII at effector cells by magnifying
the reduction in LpA by angiotensin II [23]. Alpha-1 adrenergic
influences within the kidney primarily affect vascular resistances.
However, the kidney seems to be less susceptible than is the
systemic circulation to a1-adrenergic influences [24]. In contrast,
a2-adrenergic agonists primarily decrease the glomerular ultrafil-
tration coefficient, an effect that is mediated via interactions with
angiotensin II [23]. These interactions among various subsets of
Congestive
heart failure
Renal vasoconstriction
and decreased glomerular
ultrafiltration coefficient
Sepsis
Decreased glomerular
filtration rate
Adrenergic nerves
Angiotensin II
Prostaglandins
Nitric oxide
Volume depletion
Antidiuretic hormone
Tubuloglomerular feedback
–
–
+
+
+
+
Fig. 1. Functional renal failure. This syndrome
commonly derives from three major conditions:
volume depletion, congestive heart failure, and
sepsis. These conditions, by a variety of
mechanisms, constrict the renal vessels and
decrease the glomerular ultrafiltration
coefficient, thus reducing GFR without
damaging the renal parenchyma. Major
influences dictating these events in the kidney
are vasoconstrictor systems such as angiotensin
II (AII), adrenergic nerves, ADH and, under
certain circumstances, tubuloglomerular
feedback activity. All these potential
vasoconstrictor systems are intimately
interrelated and are counteracted effectively in
the kidney by vasodilatory systems such as local
nitric oxide and prostaglandin generation.
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the adrenergic and angiotensin II systems can be further magni-
fied by treatments applied in the intensive care unit, where agents
possessing both a1- and a2-adrenergic activity are commonly
administered to support blood pressure. A pure a1-adrenergic
agonist such as methoxamine can actually “spare” renal function
when compared to more general adrenergic agonists such as
norepinephrine [24]. Let me offer one caveat, however: further
complex compensatory mechanisms governing intrarenal AII ac-
tivity can render the response to eliminating renal nerve activity
unpredictable [25]. One would predict that acute removal of
adrenergic activity would result in vasodilation. In fact, however,
this maneuver causes transient acute increases in angiotensin II
activity and constancy in GFR and renal blood flow, possibly by
altering proximal tubular reabsorption and activating the renin-
angiotensin system [25]. However, subacute removal of adrenergic
activity exerts further complexities to this relationship because it
enhances the kidney’s response to angiotensin by increasing the
number of AII receptors [26]. In addition, renal vascular sensitiv-
ity to AII increases after subacute renal denervation because of
major upregulation of AII receptor number [26]. This effect does
not appear to be mediated by diminished b-adrenergic activity
[27] or by a reduction in the amount of local AII available to cause
homologous desensitization of AII receptors [28]. In summary,
removal of adrenergic activity, either by pharmacologic means or
by renal denervation, produces complex effects on net renin-
angiotensin activity within the kidney, both by activating renin-
angiotensin activity and by altering angiotensin receptor number.
Therefore, removal of adrenergic activity might not result in renal
vasodilation.
Other factors modifying renal vasoconstriction and GFR. The
important role of prostaglandins in buffering the effects of renal
vasoconstrictors has been reviewed in detail elsewhere [7, 12, 13,
15]. However, prostaglandins are not the only paracrine factors
that influence the degree of renal vasoconstriction in pre-renal
conditions. Nitric oxide also plays a major role [29–32]. Previous
studies from our own [14] and other laboratories have shown that
inhibition of nitric oxide synthase (NOS) increases renal vascular
resistance and decreases nephron plasma flow and filtration rate,
while concurrently increasing systemic blood pressure by increas-
ing systemic vascular resistance. This hemodynamic response
implies an important tonic influence of NO on systemic as well as
renal vascular resistance [14, 28]. Nonetheless, the systemic and
renal effects of NO blockade can be disassociated. For instance, in
the normal rat, when AII receptor blockers are administered
during NOS inhibition, the effect of NOS inhibition on systemic
blood pressure remain, yet renal vascular resistance, nephron
plasma flow, and GFR return to normal [14]. These results
indicate that although NO exerts normal tonic vasodilatory influ-
ences on systemic vascular resistance, in the kidney NO is
primarily a major antagonist of vasoconstrictors such as AII.
Other studies have suggested that the activity of intrarenal NO is
also sustained by renal adrenergic activity, primarily via a2-
adrenergic receptors [28, 29]. The kidney’s response to NOS
inhibition was blunted by renal denervation or by the a2-adren-
ergic antagonist yohimbine, and was restored after denervation by
infusion of an a2-adrenergic agonist [28, 29]. The reports that
NOS mRNA in the kidney is more prevalent during salt depletion
imply that NO production can increase, thereby mitigating pre-
renal failure [30]. But this hypothesis cannot be reconciled with
the repeated observation that the renal vasoconstriction resulting
from acute NOS inhibition is amplified by volume expansion [31,
32]; this observation implies a lesser role for endogenous NO
during volume contraction [31, 32]. The present case was further
complicated by the use of cyclosporine, a known endothelial toxin
and inhibitor of normal endothelium-dependent vasodilation [16,
17]. Gabbai et al have shown that the renal vasodilatory response
to glycine infusion is mediated by NO, blunted by cyclosporine,
and restored after cyclosporine administration by the NO sub-
strate L-arginine [18]. Therefore, it is conceivable that cyclospor-
ine administration also limits the normal renal vasodilatory re-
sponse to the large protein load, an effect that is apparently
mediated by nitric oxide.
Tubuloglomerular feedback. The physiologic processes of glo-
merulotubular balance (GTB) and tubuloglomerular feedback
(TGF) comprise a system that coordinates glomerular filtration
with tubular reabsorption, and thereby stabilizes both GFR and
fluid delivery to the distal nephron [33–39]. Glomerulotubular
balance, which determines the dependence of late proximal flow
on SNGFR, is mediated by the load dependence of proximal
tubular reabsorption [40]. Tubuloglomerular feedback is respon-
sible for an inverse dependence of SNGFR on late proximal flow
and is mediated by complex communication between the macula
densa and the glomerular microvasculature. The ability of TGF to
alter SNGFR in response to changes in late proximal flow is
non-linear and saturable. There is a narrow range of flows over
which TGF is most reactive. Under normal conditions, GTB and
TGF interact to position the normal flow rate somewhere within
this narrow range such that TGF is partially activated (Fig. 2).
This activation causes SNGFR to be less than it would be if TGF
were eliminated. Increases in late proximal flow rate cause renal
vasoconstriction and a reduction in SNGFR, as depicted in the
normal profile in Figure 2. The basal tone that TGF exerts on
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Fig. 2. The relationship between late proximal flow rate (VLP) and the
resulting single nephron GFR (SNGFR), which describes the tubuloglo-
merular feedback system. The system is not static and can adapt by either
(1) desensitizing, that is, decreasing the efficiency of the system in and
around its normal flow rate; (2) resetting, that is, altering the relationship
between late proximal flow rate and the resulting SNGFR; and (3) altering
the basal value for nephron filtration rate, at which there is no tubuloglo-
merular feedback influence (SNGFR).
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SNGFR can be increased when proximal reabsorption decreases
(as during acute tubular dysfunction) or when the TGF mecha-
nism is reset so that it engages at a lower rate of tubular flow.
In a state of uncomplicated pre-renal azotemia, in which the
proximal tubule responds normally to neurohumoral influences,
fractional proximal reabsorption increases. This rise should re-
duce the tonic influence of TGF over SNGFR and allow SNGFR
to increase. We have utilized a means whereby proximal tubular
flow can be measured without being interrupted [37], and we have
employed this technique to test for symmetry of the TGF function
with respect to ambient tubular flow [38, 39]. A sustained alter-
ation in late proximal flow, whether induced indirectly by an acute
change in systemic volume status [38] or directly by supplemented
early proximal flow at the level of the single nephron [41], causes
TGF to reset such that the ambient flow continues to reside along
the steep portion of the new TGF function (Fig. 2). Studies have
demonstrated temporal adaptation or resetting of TGF when flow
into the loop of Henle increases. Contrasting adaptive phenom-
ena also must occur with reductions in delivery to the macula
densa, which should occur in a setting of increased proximal
reabsorption. The net effect is that the tonic influence of TGF
over SNGFR is reduced in settings of acute volume depletion [38].
Therefore, when the pre-renal state is associated with increased
proximal reabsorption, TGF should mitigate the pre-renal reduc-
tion in GFR, although this mitigation is partially countervailed by
TGF resetting. Studies from this laboratory also have shown that
local inhibition of macula densa NOS increases the reactivity of
the TGF response and shifts the response leftward relative to the
ambient flow, thereby increasing the basal influence of TGF over
SNGFR [42]. In other words, endogenous NO within the macula
densa likely exerts a tonic desensitizing influence on TGF. Given
that the influence of NO on renal function appears to be reduced
during volume depletion [31, 32], it is possible that the reduced
NO activity in this setting further enhances TGF efficiency, but
these specific issues have not been examined experimentally. This
degree of leftward resetting would contribute to a further reduc-
tion in GFR (Fig. 2). Tubuloglomerular feedback also could
contribute to renal vasoconstriction in the presence of modest
proximal tubular injury [43, 44], as in patients with major trauma
or severe infection who are on the verge of developing acute
tubular necrosis. Proximal tubular injury increases the delivery of
fluid to the macula densa and leads to TGF-mediated renal
vasoconstriction [36, 43]. Pre-renal azotemia or functional renal
failure often precedes parenchymal injury and acute tubular
necrosis [45]. One can logically assume that there are periods in
which a prerenal pattern of vasoconstriction must coexist with
early proximal tubular injury and that proximal tubular injury
could contribute to the renal vasoconstriction that characterizes
the prerenal condition via TGF-mediated mechanisms. One could
view this transitional period of early dysfunction of tubular
reabsorption as heavily affected by the TGF-mediated defense
mechanism, which limits the filtered load per nephron. In this
setting, TGF-mediated renal vasoconstriction potentially fore-
stalls tubular injury by reducing the energy demands of the tubule
[46, 47].
Fluid loading with solutes other than NaCl reduces TGF
responsiveness (Fig. 2). The pattern of effects of increased solute
load (for example, glucose, mannitol) on TGF is a reduction in
homeostatic efficiency or, as depicted in Figure 2, a desensitized
TGF system, in which the slope of gain around the normal flow
rate is markedly reduced. This reduction has been demonstrated
in older studies utilizing traditional methods for the evaluation of
TGF during microperfusion of Henle’s loop with solutions con-
taining glucose or mannitol [33, 35]. Tubuloglomerular feedback
responsiveness is also essentially eliminated in non-diabetic rats
made hyperglycemic by systemic infusion of glucose [48]. This
blunting of TGF responsiveness during hyperglycemia is not
merely the consequence of glucose effects within the tubular
lumen. If the loop of Henle of hyperglycemic normal rats is
perfused from the late proximal tubule with tubular fluid that is
glucose-free, partial inhibition of TGF activity exists. This finding
implies that both extraluminal and intraluminal components
inhibit TGF during systemic hyperglycemia [48].
We recently assessed the ability of TGF to stabilize flow in
free-flowing proximal nephrons in hyperglycemic rats with insulin-
treated streptozotocin-induced diabetes [49]. The homeostatic
efficiency of TGF was markedly reduced in these animals, and this
effect could not be explained by changes in tubular reabsorption
(Fig. 3). One might predict that the reduction in TGF efficiency in
diabetic rats could be the consequence of intraluminal glucose
reducing loop of Henle and macula densa reabsorption. However,
specific studies utilizing micropuncture have observed that loop of
Henle reabsorption and the macula densa NaCl signal were
Fig. 3. Dependence of single-nephron glomerular filtration rate
(SNGFR) on late proximal flow rate in control animals (E) and in
hyperglycemic diabetic animals (F). Two major changes occur as a result
of diabetes and hyperglycemia. First, the SNGFR increases. Second, the
sensitivity of TGF operation is greatly diminished, whereby the slope
around the operating point is decreased. Triangles denote midpoints.
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essentially normal, while TGF homeostatic efficiency was mark-
edly reduced [49]. Although this response would be expected to
reduce the basal influence of TGF on GFR, reduced TGF
efficiency also could exacerbate renal NaCl and water losses
during an osmotic diuresis. Solute excess in the form of mannitol,
glucose, and probably urea suppresses TGF efficiency and can
contribute further to urinary NaCl and water losses in addition to
the effects of osmotic diuresis [33, 35, 48–50]. Solute-induced
suppression of TGF activity interferes with appropriate reductions
in GFR. The relative inability of appropriate TGF mechanisms to
suppress GFR during solute diuresis results in a higher TGF that
could magnify potential NaCl and water losses. In this sense, the
normal TGF response should be viewed as a critical mechanism
for the conservation of NaCl and water. The greater water loss is
recognizable by the patient’s tendency to hypernatremia; it is
treated by the administration of free water.
A special case: Pre-renal failure in sepsis. The sepsis syndrome,
particularly gram-negative sepsis, is characterized by a reduction
in systemic vascular resistance and an increase in cardiac output
followed by hypotension [51–53]. These cardiovascular events can
be recognized early in the ICU during invasive monitoring,
because cardiac output increases prior to significant hypotension.
Certain aspects of this syndrome have been attributed to cytokine
induction of NOS and the subsequent overproduction of nitric
oxide, which reduces systemic vascular resistance. However, renal
dysfunction in sepsis often resembles pre-renal failure and is not
so much the consequence of systemic hypotension as of renal
vasoconstriction. This event stands in contrast to the observation
that overall systemic vascular resistance is markedly reduced in
early sepsis by excess NO production. The questions arise, what is
the mechanism of renal vasoconstriction, and why is the response
of the renal vasculature opposite to that of the remaining systemic
vasculature?
Schultz and Raij have demonstrated that when lipopolysaccha-
ride (LPS) is administered to rats, GFR decreases; if the non-
selective NOS inhibitor L-N-arg-methylester (L-NAME) is also
administered, the renal dysfunction is aggravated in part because
glomerular thrombosis occurs [54]. Recent studies from our
laboratory have confirmed that pre-renal failure after LPS admin-
istration is markedly worsened by the simultaneous administration
of the non-selective NOS inhibitor L-N-monomethylarginine (L-
NMMA), by increasing renal vasoconstriction rather than by
producing glomerular thrombosis. When the selective blocker of
inducible NOS, L-N-imino-lysine (L-NIL), or the inhibitor of
iNOS gene transcription, diacetyl-hydropyrimidine (DAHP), is
applied to LPS-treated rats, however, GFR is no longer sensitive
to LPS. These observations suggest that renal vasoconstriction
due to LPS results from feedback autoinhibition of constitutive
endothelial NOS when NO is produced by iNOS. We also have
demonstrated that agonist-stimulated constitutive NOS is essen-
tially eliminated after the administration of LPS and LPS 1
L-NMMA, and that L-NIL therapy normalizes endothelial NOS
activity [55].
Nitric oxide in the kidney thus is critical to balancing the effects
of various renal vasoconstrictors, particularly AII and renal
nerves, and the pathogenesis of pre-renal failure and renal
vasoconstriction in sepsis is somewhat more complex than that
which results from pure volume depletion or congestive heart
failure. Selective therapies targeting inducible NOS activity might
find practical use in the future.
Summary
Pre-renal failure is a physiologic response to severe volume
depletion, congestive heart failure, or sepsis. In certain instances,
pre-renal failure can protect the tubule against injury due to
energy depletion. Pre-renal azotemia can occur in the presence of
a generous urine flow when the kidney is presented with a large
osmolar excretory burden. Large solute loads can magnify urinary
volume losses via an osmotic diuresis and by diminishing the
efficiency of tubuloglomerular feedback mechanisms. In the pa-
tient with sepsis, iNOS inhibitors can reverse both renal vasocon-
striction and the characteristic systemic cardiovascular abnormal-
ities. Perhaps these agents will play a clinical role in the future in
the treatment or prevention of renal failure due to sepsis.
QUESTIONS AND ANSWERS
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology, New
England Medical Center, Boston, Massachusetts): Clinical experi-
ence indicates that individuals respond differently to renal hypo-
perfusion in terms of whether they will develop pre-renal
azotemia versus acute tubular necrosis. What factors determine
this variable response? Would you comment on the transition
from pre-renal azotemia to acute tubular necrosis?
DR. BLANTZ: This will be a critical area of human and animal
research in the next few years. In certain clinical conditions,
particularly in the postoperative cardiac patient, a transitional
period of functional renal failure often evolves into ATN if the
cardiac index does not improve. The question is: can one inter-
vene with a renal vasodilator, reverse the pre-renal process, and
somehow prevent or delay the ATN? I am skeptical. I do think
that the pre-renal failure component of this response actually may
somewhat protect renal function. In fact, clinical efforts at in-
creasing GFR by raising renal blood flow can impose additional
reabsorptive obligations on the proximal tubule [46]. In these
circumstances, toxic exposure can promote additional renal injury.
We cannot assume that the tubule is not injured during the
pre-renal phase, because in most instances we deliver potentially
toxic substances, or endogenous substances circulate that are
potentially toxic to the tubule. So the original question has
become more complicated: does reversal of pre-renal azotemia
prevent, or does it increase the likelihood of, acute tubular
necrosis? If we believe that reversing the pre-renal process
prevents ATN, we are assuming that pre-renal failure somehow
imposes an ischemic condition on the kidney. The literature
suggests that that is probably not the case. The kidney is quite
different from the heart. Increasing blood flow to the heart,
depending on the work demands at the time, likely reverses or
prevents ischemia. If one increases renal plasma flow, GFR
usually increases. Thus, vasodilation does not just increase sub-
strate and oxygen delivery; the consequent increase in GFR
should impose more demands on the organ by increasing tubular
reabsorption consequent to the increase in filtered load. We
cannot be certain about whether increasing GFR puts the kidney
at risk. Spontaneous reversal of pre-renal failure should always be
beneficial, but imposing renal vasodilation might not always be of
benefit for the kidneys.
Some nitric-oxide-deficient patients might be at risk for more
severe pre-renal events. That particular subset of the population
might be one to examine. Atherosclerotic or hypertensive patients
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might exist in a relative nitric-oxide-deficient state. I am con-
cerned that interfering with normal renal vasoconstrictor pro-
cesses will lead to disappointing outcomes, an increase in inci-
dence and severity of acute tubular necrosis.
DR. MADIAS: I have a followup question. Patients with conges-
tive heart failure seem to tolerate very low perfusion pressures for
a long period. Rather than developing acute tubular necrosis, they
remain in what we perceive as functional azotemia while, let’s say,
patients with the same perfusion pressures (secondary to volume
depletion or hemorrhage) march on to ATN. Could you comment
on potential mechanisms for this difference?
DR. BLANTZ: I agree that acute tubular necrosis is rarely
observed in patients with severe congestive heart failure. I don’t
think it is necessarily the agents that are being used to treat heart
failure that provide benefit. Perhaps a temporal adaptation to
congestive heart failure allows the kidney to adapt to this adverse
circumstance. The only time I have seen profound acute tubular
necrosis in the setting of congestive heart failure was in a patient
who had had a massive, acute myocardial infarction. On the other
hand, acute volume depletion might not allow for such compen-
sation. This is my own opinion, and it is not based on any
experimental evidence whatsoever.
DR. MADIAS: Do you think ANP might play a role in preventing
acute tubular necrosis in patients with congestive heart failure?
DR. BLANTZ: I doubt that ANP plays a major ameliorating role
in this circumstance. There’s not much evidence to support that
notion.
DR. THOMAS ZIEGLER (Associate Professor of Medicine; Univer-
sity of California, San Diego; La Jolla, California): Pneumonia,
empyema, pleural effusions, tuberculosis, and lung abscess all are
classical causes of SIADH. Has “status post lung transplant”
joined that list? Could some of the interesting and extreme
features of today’s case flow from a superimposition of SIADH on
vasomotor, functional renal failure? Let me extend that sugges-
tion further. If we had had access to a direct peptide antagonist of
ADH for clinical use, would it have made your patient better, or
would it have been malicious to treat him with an infusion of
ADH antagonist? Given that we don’t yet have such a peptide
antagonist, when, if ever, would you treat a patient with demeclo-
cycline to block the renal effects of ADH while you are promoting
saline or colloid volume expansion?
DR. BLANTZ: The real question is whether the patient has an
appropriate release of ADH or SIADH; it is often difficult to
determine an appropriate ADH level. Let me take the question
out of this setting, because I can’t give you experimental evidence
in support of or against your comment. Let us take the burn unit
patient, for example. Even well-hydrated burn patients exhibit
seemingly high ADH levels, which might be somehow appropriate
for their horrible circumstance. I don’t know whether it is
inappropriate in this circumstance or not, but they tend to
manifest signs of volume depletion while excreting normal and
even elevated urine volumes. Patients exhibit low fractional
excretion of urea, which is likely ADH dependent. I have difficulty
discerning, even in some classical elevated ADH states, how
appropriate or inappropriate is the elevated ADH level. Some
interesting data do relate to your second point, however. Vaso-
pressin antagonists can be very helpful in congestive heart failure,
because aquaporin expression is vasopressin dependent. A water
diuresis would be greatly beneficial. Papers coming out in the next
year suggest that in animal heart failure models, certain aquapor-
ins are recruited in the kidney by a vasopressin-dependent signal-
ing mechanism that magnifies the prevailing stimulus for water
absorption. I would prefer a vasopressin antagonist over deme-
clocycline, an agent which I have never used with much success.
DR. RAVINDRA L. MEHTA (Associate Professor of Medicine,
University of California, San Diego): I am intrigued by your
presentation of Dr. Schwartz’s new data on the effect of NOS in
the setting of sepsis. A similar situation exists in cirrhotic patients
who also present with a high cardiac output state. These patients
also might have a systemic excess of NO. You have shown us very
elegantly that the pre-renal factors are vasoconstrictive and
contribute to a further decline in GFR, the effects being that
tubular metabolism is preserved and high-energy-demanding pro-
cesses aren’t initiated. Could the corollary be true? That is, could
a high NO state (a high vasodilator state) initiate a compensatory,
vasoconstrictive response?
DR. BLANTZ: Data in the gastroenterology and the general
scientific literature indicate that inducible NOS (iNOS) activity is
increased in severe cirrhosis [56]. Whether this increase is due to
the leaky gut and thus endotoxin appearing in the circulation, or
whether other mechanisms are operative is not clear. Transcrip-
tional activity for iNOS appears to be elevated in cirrhotic models.
A second mechanism likely relates to elevated plasma arginine
levels. After arginine is normally absorbed in the gut, the liver
controls plasma arginine levels through the urea cycle by convert-
ing arginine to ornithine. Patients with reasonably normal hepatic
function have fairly stable arginine plasma levels regardless of
arginine intake [57]. On the other hand, patients with severe
hepatic failure or hepatorenal syndrome exhibit progressively
increased arginine levels in plasma, possibly because of either
portal-systemic shunting of arginine, bypassing the liver, or liver
failure. For these two reasons, you are right: arginine substrate
levels are elevated in a setting in which transcriptional activity for
inducible NOS is increased. The response of the constitutive NOS
side of the equation, however, is less well defined in cirrhosis. The
data supplied by Dr. Schwartz [55] in some way might be
applicable to the cirrhotic state, but I say that in a speculative
fashion. It is clear that excess inducible NOS activity can inhibit
the constitutive NOS. Also Dr. Gabbai and others have suggested
that the role for NO or constitutive NOS in the kidney is different
than it is in the systemic vasculature, in that NO does not act as a
primary vasodilator in the kidney; rather, it acts as an antagonist
of vasoconstrictors such as angiotensin II [14]. This mechanism
might explain why the kidney exhibits vasoconstriction while
systemic vascular resistance is remarkably low throughout the
body. Systemic vasodilation alone contributes to salt retention;
however, it doesn’t cause the vasoconstriction. I think it is an
intriguing mechanism, but I would not suggest running out and
giving L-NIL, an iNOS inhibitor, to every cirrhotic patient.
Nevertheless, it is something to consider, especially if the sepsis
data hold up, which in an acute setting is probably more analogous
to what we see in cirrhosis in a chronic setting.
DR. MEHTA: I was questioning a different pathophysiologic
aspect. We know that in cirrhotic patients with peripheral pooling
of blood, there is the possibility of shunting blood away from the
kidney. Is it possible that the inciting event for renal vasoconstric-
tion is not the peripheral shunting but, rather, excessive vasodi-
lation?
DR. BLANTZ: This has been a mystery for a while. When the
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potent vasodilator minoxidil first became available as an antihy-
pertensive agent, some physicians administered it without a
diuretic [58]. A resulting clinical syndrome occurred reproducibly
and consistently. The blood pressure didn’t decrease appreciably,
and the patient relentlessly accumulated salt and water. The
peripheral vasculature does talk to the kidney, there is no doubt
about that, possibly through adrenergic communications, but I am
not sure that this effect produces renal vasoconstriction. I recall
no model demonstrating that primary systemic vasodilation per se
elicits renal vasoconstriction. The only other condition that I
recall is thyrotoxic storm, which I haven’t seen more than once or
twice in my life. Thyrotoxic storm is characterized by high-output
cardiac failure, wide open capillary beds, and extreme increases in
BUN and serum creatinine. The mechanism you are postulating
might be operative in that condition. The actual mechanism of
how vasodilation elicits responses in the kidney is totally unknown
to me. I would suspect renal nerves are candidates, and maybe
angiotensin II, but on the whole, the mechanisms are ill-defined.
DR. MADIAS: You referred to the toxicity of an NO product,
peroxynitrite, to various cells, including the renal tubule, and its
role in ischemic reperfusion in various organs. Some elegant data
from Dr. Goligorsky’s group support the view that inhibiting
inducible NOS might attenuate ischemic acute renal failure in the
rat [59]. Could you please comment on the possible relevance of
these observations for sepsis-induced renal dysfunction?
DR. BLANTZ: Work from the University of Colorado suggests
that after ischemic damage to the proximal tubule, blockade of
NOS benefits the kidney [60]. I believe that they thought this
reflected the activity of an inducible form, but other NOS isoforms
might have been producing NO. I presume this implies that
peroxynitrite generation was causing membrane damage. Per-
oxynitrite formation in large quantities not only requires excess
production of NO but also requires an excess of oxygen-free
radicals (O2
2). This means that the oxygen radical generation is
sufficient to overload the capacity of superoxide dismutase to
consume or metabolize it. Renal ischemia qualifies as one of these
circumstances. I don’t know of any reports in the literature saying
that NOS over-activity alone in the absence of oxygen radical
generation produces enough peroxynitrite to generate tubular
membrane damage. As you know, if oxygen radical generation is
not great, there is generally enough superoxide dismutase to mop
up small amounts of oxygen radicals, and the reaction requires
both NO and O2
2 to produce peroxynitrite in large quantities. I
agree with you that peroxynitrite has a potential for significant
membrane damage. The group you mentioned already has sug-
gested that, in ischemic models, NOS blockade has been benefi-
cial.
DR. MEHTA: I have a different question related to clinical
practice. We all use fractional sodium excretion and, more
recently, fractional urea excretion to define prerenal failure. Do
you see an association between these two tests, that is, a high
fractional excretion of sodium and a low fractional excretion of
urea? Would such an association be a useful tool for identifying
the kind of patient you presented? Second, since we cannot
change the management of the burn unit patient and the trans-
plant patient in need of high nutritional supplements, can we
prevent the clinical consequences?
DR. BLANTZ: I hate to be a skeptic, but the original utility of the
fractional excretion of sodium (FENa) or renal failure index was
restricted primarily to the oliguric or the nearly oliguric patient.
When urine volumes are in the range of 2 to 3 liters/day, it
becomes a less valuable index. As an example, if a patient
exhibited a FENa of 1%–2%, would that level be low if the daily
urine volume were 2700 cc? In circumstances in which the FENa is
not so helpful, as in a polyuric patient, the demonstration of 20%
fractional excretion of urea suggests that the patient doesn’t have
ATN. I seriously doubt that any patient with full-blown ATN
could exhibit such a low fractional excretion of urea.
DR. MADIAS: Has the utility of the fractional excretion of urea
been studied formally in the evaluation of patients with renal
hypoperfusion?
DR. BLANTZ: Recent abstracts at the last two ASN meetings
suggest the superiority of a low fractional excretion of urea over
the sodium indices. I don’t know whether these data have been
published. As Dr. Mehta suggests, even in clinical circumstances
with normal urine volumes, a low fractional excretion of urea
suggests reversibility.
DR. ROBERT STEINER (Clinical Professor of Medicine, Depart-
ment of Nephrology, University of California, San Diego): I have an
observation and a question. In a case like this, we lose the value
of urea as a surrogate marker for products of protein catabolism,
which are major contributors to the severity of uremia. In fact, this
patient was less azotemic as regards to other uremic toxins than
was indicated by the high BUN. If a patient’s blood urea doubles
because the fractional excretion falls in half, in a sense should we
“discount” the patient’s azotemia by 50%? Second, I think the
patient presented might have had a concentrating defect. When
one estimates his minute osmolar excretion, it is perhaps too low
to justify saying that he had a solute diuresis that was solely
responsible for his less-than-maximally-concentrated urine. Are
any of the observations you’ve made relevant to the generation of
a concentrating defect in this patient?
DR. BLANTZ: Chuck Kleeman and Alexander Leaf created a
variety of experimental curves that related urine flow rate induced
by osmotic diuretics such as mannitol and the urine concentration
in mOsm/kg H2O. In general, these exponential curves began at
either minimal urine tonicity or maximal urine concentration and
moved asymptotically toward isotonicity similar to plasma values.
Whether our patient “fell off” this normal curve depends on which
experimental data you choose. In the Leaf model, our patient fell
off the curve. On the other hand, that curve might have been
generated with 18-year-old volunteers, and our patient doesn’t fall
into that category. He was not a well person before his lung
transplant. The curves generated by others would have placed our
patient at 1.3 mOsm/min osmolar excretion, correlating with a
urinary osmolality of around 850 mOsm/kg H2O. Our patient
concentrated to 650–690 mOsm/kg H2O at this osmolar excre-
tion.
The other intriguing element of this case is that I have always
understood that the only way you replenish urea in the papilla is
by having a high ADH and a low urine volume. The collecting
duct permeability of urea is not the only factor to consider. The
urea concentration gradient also must be considered. The abso-
lute contribution of urea to urine osmolality was only 450–500
mOsm/kg H2O in this patient. Since the fractional excretion of
urea was 25%, major reabsorption of urea had to be driven by a
favorable gradient for entry into the papillary interstitium. This
requires that papillary urea concentration had to be lower than
450 mOsm/kg H2O and possibly considerably lower. It is quite
reasonable to speculate that this patient’s papillary urea had been
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relatively low for some time before he was evaluated, thus creating
a favorable gradient for urea movement into the papillary inter-
stitium. Whether the lower papillary urea concentration was
attributable to the fact that he was sick and protein malnourished
prior to entry to the hospital and that somehow he had not been
able, in spite of his protein intake, to restore papillary urea, I don’t
know. Elevated ADH alone is not sufficient if the gradient is not
favorable.
DR. DAVID M. WARD (Professor of Medicine; Director, Dialysis
and Clinical Nephrology; University of California, San Diego; La
Jolla): I’d like to follow up on this question regarding urine
osmolality and the fact that this man didn’t get his urine osmola-
lity above 650 mOsm/kg H2O when he supposedly had pre-renal
azotemia. The data go back to Glasgow with Robin Luke and
Adam Kennedy maybe 25 years ago [61]. The data predicted that
if urine osmolality were above 500 mOsm/kg H2O in a dehydrated
patient, volume replacement would restore renal function,
whereas an osmolality below this level indicates that you had
“crossed the Rubicon” where acute tubular necrosis sets in.
Obviously there is a gray zone between pre-renal azotemia and
acute tubular necrosis. Most of your discussion today focused on
the neurohumoral reasons for the patient’s clinical status. But my
concern is that he was polyuric when he should have been oliguric,
and his urine osmolality might not have been maximal. Does that
possibility suggest to you that in addition to neurohumoral
problems, a degree of functional proximal tubular damage or
dysfunction existed?
DR. BLANTZ: I am not concluding that the patient did not have
a water-reabsorptive defect. As you recall, the urea reabsorption
that occurs in response to ADH is primarily in the terminal
collecting duct, whereas the ADH effect on water movement is,
for the most part, all along the collecting duct, or at least more
proximal. One could speculate that with the large urea load that
was filtered in this patient, he had sufficient urea in his upper
collecting duct to retard water movement out of the collecting
duct. The real question is, why did he continue to have such
massive urea reabsorption? That is the issue with which I have the
most difficulty. You’re implying that he should have exhibited a
higher urine osmolality. The reason he didn’t have a higher urine
osmolality is because he didn’t have enough urea in the urine due
to its reabsorption, and now we are in a circular argument. The
driving force for urea reabsorption has to be a relatively low
papillary urea concentration or, as Dr. Steiner has suggested, an
astounding medullary blood flow removal, in which urea is washed
out of the patient’s medulla, perpetuating a favorable concentra-
tion gradient at a given ADH level to keep recycling urea into the
papilla. I would have preferred the patient’s urine concentration
at 900 mOsm/kg H2O, but if you ask me what solute would be
required to create this concentration, it has to be urea. So, I don’t
know exactly how to solve that problem because the problem is
the cause, and so on in a circular argument. Part of the problem
may be that if you perform a water-deprivation test on someone
who has been in the hospital, I seriously doubt that many of them
would achieve a urine osmolality of 1200 mOsm/kg H2O. If you
evaluate 18-year-olds who are members of a rugby team, a fair
percentage of them would be able to maximally concentrate their
urine. Prior protein malnutrition might have contributed to the
lower medullary/papillary urea content in this particular patient.
DR. MADIAS: Evidently, some patients have been described who
developed oliguric acute renal failure following administration of
large doses of mannitol resulting in great accumulation of man-
nitol in plasma [62, 63]. Could you comment on these reports?
DR. BLANTZ: I am certain you could “dry out” a patient with
mannitol, so I’m not surprised that you could produce oliguria,
especially after all the mannitol is excreted. As with massive urea
diuresis, mannitol provides the clue pointing to the presence of a
polyuric state, a clue of plasma hypernatremia that is not observed
as readily with hyperglycemia and glucosuria. Years ago we
described some experiences with the use and abuse of mannitol
[5]. In addition to producing hypernatremia and profound volume
depletion, large-volume mannitol administration can produce
wide swings in plasma potassium concentration. If one gives 100 g
of mannitol, the serum potassium will increase transiently, but
eventually the patient will become hypokalemic if mannitol ad-
ministration continues. I presume that oliguric renal failure after
mannitol administration is a function of massive volume depletion
rather than of any intrarenal effect.
DR. BRIAN MCDONALD (Head, Nephrology Division, Naval Med-
ical Center, San Diego): Not uncommonly, a consulting nephrolo-
gist encounters a patient similar to the one you presented today in
whom it appears that a functional component might respond to
volume expansion. However, our colleagues are commonly reluc-
tant to rapidly infuse fluids. Often physicians exert pressure on us
to perform a dialytic procedure for reduction of BUN. Given the
artful pathophysiologic scheme you presented, is it conceivable
that provision of an isovolumetric dialysis to reduce the endoge-
nous solute load might help, or could it worsen the pre-renal state
due to renal vasospasm?
DR. BLANTZ: You have raised a ticklish point in “political
nephrology,” shall we say. I would like to say that I have never
given in to that temptation, but I would be lying. We have, in fact,
dialyzed patients who had high blood urea concentrations, al-
though we knew that other treatments would decrease the urea,
such as giving more fluids. But you have raised an important point.
One could conjecture that if dialysis were utilized to remove urea,
we could have cured this patient’s problem. However, this seems
an expensive way to produce a cure, since D5W must be less
expensive than the costs of a nurse and a dialysis session. I see
your point, and dialysis is another approach for removing urea.
This patient ran into real difficulty because many lung transplant
surgeons and some burn treatment physicians have a real aversion
to making the patient’s net volume positive. They believe that a
wet lung is the predisposing template upon which transplant
rejection occurs. They tend to keep patients very dry, and it is hard
to convince these doctors otherwise. So if you think the patient is
azotemic as a result of elevated protein catabolism, your hand may
be forced, no doubt about it. We have dialyzed for less-academic
reasons, so I suppose that would be a potential treatment re-
sponse if administering fluids and NaCl is not a treatment option.
DR. FRANCIS B. GABBAI (Chief, Nephrology Section, Veterans
Affairs Medical Center, San Diego; La Jolla): I’d like to return to
the issue of whether pre-renal azotomia is good or bad. One might
think that a pre-renal condition with a decreased GFR is good for
proximal tubular cells because the filtered load decreases. But in
pre-renal conditions, proximal tubular reabsorption, as indexed by
fractional reabsorption, is increased. If tubuloglomerular feed-
back is trying to drive tubular function to its maximum capacity,
isn’t there a contradiction between these two mechanisms? A
reduction in GFR would be beneficial, while an increase in
reabsorption would put the cell at increased risk.
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DR. BLANTZ: You raise an interesting point, and I am going to
offer a view that is borderline radical. Many of our textbooks state
that with volume depletion, proximal reabsorption increases. In
fact, I challenge anyone to find a single publication demonstrating
that absolute proximal reabsorption increases as a result of
volume depletion. Ed Weinman and Mike Weiner several years
ago [64], and Bob Steiner and I [9], examined volume depletion
with micropuncture techniques. We could not find a time at which
absolute proximal tubular reabsorption increased. The reduction
in GFR was always a contributing factor to the increase in
fractional reabsorption. One could argue that in the more severe,
second phase of volume depletion, GFR reduction via angiotensin
II or renal nerves preserves salt and water and proximal tubular
integrity. I wonder, however, whether reductions in blood flow
and GFR in response to volume depletion really are risks for
tubular injury. This second phase of volume depletion and
pre-renal azotemia might subserve a beneficial purpose by actu-
ally reducing the risk of renal damage. In older studies in isolated
perfused kidneys, oxygen consumption was primarily determined
by filtration rate [65]. This shouldn’t be a surprise to anyone,
because oxygen consumption is primarily linked to sodium/potas-
sium ATPase activity and tubular reabsorption of sodium as a
function of GFR. Unless a diuretic is supplied, the best predictor
of renal oxygen consumption is the GFR. Reductions in GFR are
not always deleterious, and these decreases actually can exert a
protective effect. I argue this conclusion in part from a philo-
sophic perspective, because evolution has not discarded this renal
mechanism over the millennia. One could argue that we should
not reverse the process of GFR reduction in pre-renal conditions.
I refer you primarily to the Thurau and Boylan article in the
American Journal of Medicine, “Acute renal success,” in which
they argue that the tubuloglomerular feedback system prevents
volume losses when tubules are injured [66]. In addition to
preventing volume losses, tubuloglomerular feedback-mediated
reductions in GFR might prevent the injured tubule from being
overworked.
DR. MADIAS: Your almost iconoclastic comment brought to
mind a number of observations that have demonstrated a dose-
dependent, bimodal effect of angiotensin II on proximal tubule
sodium and fluid reabsorption, low concentrations increasing and
high concentrations decreasing proximal functions [67–70]. In
fact, several laboratories, including our own, have shown this
differential effect of angiotensin II on the activity of the proximal-
tubule sodium/hydrogen exchanger and sodium/bicarbonate sym-
porter [69, 71]. Can you put these observations in a clinical
context, and do you think that these data are relevant to the idea
that you just expressed?
DR. BLANTZ: I can only quote data that I have already cited that
have been largely misinterpreted. Those are the studies in which
Di Nicola and Gabbai examined NOS blockade and the effect on
the tubule and glomerulus [14]. When they gave losartan, an
angiotensin II receptor blocker, it eliminated the stimulatory
effects of angiotensin II on reabsorption. Losartan alone modestly
reduced the absolute proximal tubular reabsorption. Interestingly,
losartan also totally prevented the effect of NOS blockade, which
was to reduce proximal reabsorption. It would appear that NO
exerts a modulating influence on the inhibitory component of
angiotensin II. Studies have shown that when one perfuses the
peritubular and luminal aspects of the proximal tubule, respec-
tively, with different angiotensin II concentrations, there is an
inhibitory reabsorptive influence of angiotensin II that occurs in
the sub-micromolar range, which is close to the observed angio-
tensin II concentration in the lumen of the early proximal tubule.
Additionally, the luminal angiotensin II concentration effects
appear to dominate over the peritubular effects. At high levels of
AII, it is possible that one could move into the inhibitory range,
especially under conditions of NO deficiency. The data in the
literature suggest that there are bi-directional influences of angio-
tensin II on reabsorption, which are about 2–3 log concentration
orders apart.
DR. MADIAS: Could you please comment on the renal conse-
quences of the various adrenergic substances, including low-dose
dopamine, used in ICUs.
DR. BLANTZ: The justification for low-dose dopamine therapy
has gradually assumed the position of an article of faith rather
than science. Multiple articles suggest some benefit of such
treatment. Low-dose dopamine does exert some beneficial di-
uretic effect. It should decrease proximal reabsorption. Low-dose
dopamine probably has no effects relevant to our discussion today
in terms of benefits to GFR and renal vascular resistance. Higher
doses of dopamine can spill over into alpha adrenergic receptors
with rather unpredictable renal contributions. What concerns me
more in the ICU setting is that many of our surgical colleagues
have developed what I would call a “bad habit” of infusing
nitrovasodilators on a routine basis. A favorite treatment in the
post-cardiac patient is to provide sodium nitroprusside or some
equivalent agent in rather significant quantities. I’m not sure this
therapy is based on any scientific principles, and what concerns
me, based upon comments of Dr. Mehta, Dr. Schwartz’s study
[55], and other reports in the literature, is that certain nitrovaso-
dilators inhibit intrinsic constitutive NOS activity, which we’ve
already postulated as an important buffer of renal vasoconstrictor
activity. Studies should be conducted, possibly in readily available,
circulating cells, to determine whether constitutive NOS activity is
downregulated by these exogenous nitrodonors. The paracrine
effects of exogenous nitrodonors must be significantly different
than the activity of intrinsic NOS-generated nitric oxide. There is
a generally reciprocal relationship between exogenously supplied
nitrates and the resulting reduction in endogenous nitric oxide
synthase activity. In the postoperative cardiac surgical patient,
nitrodonors can autoinhibit intrinsic NOS enzymes, thereby con-
tributing to unopposed activity of renal vasoconstrictors, thereby
increasing the likelihood of pre-renal failure.
DR. ZIEGLER: Between approximately 1930 and 1960 a huge
amount of data accumulated about urinary enzyme assay as a
diagnostic approach to acute tubular necrosis. As far as I know,
this approach was summarized in Laurence Wesson’s Physiology of
the Human Kidney [72], and no one’s used it since. The subject of
crossing the line from functional renal failure to acute tubular
necrosis is an exceedingly important issue clinically, and I’m sure
physiologically. Do you think we’ll have some modern methods
for looking at either enzyme regurgitation into blood or urine as
a way of getting a handle on early acute tubular necrosis? It seems
to me that one interesting aspect of today’s case might be that this
patient actually developed some early acute tubular necrosis but
that it remained below our current diagnostic threshold.
DR. BLANTZ: As I mentioned previously, I wish there were a
distinct border, the Rubicon as Dr. Ward calls it, between
pre-renal failure and ATN, at which physicians could raise a red
flag in the ICU and state unequivocally, “This patient has ATN.”
Nephrology Forum: Pathophysiology of pre-renal azotemia 521
There’s a tremendous overlap between ATN and pre-renal fail-
ure. If there are excessive N-acetyl-glucosaminidases, beta-micro-
globulins, and other enzymes coming out in the urine [73], the
patient should have ATN but, concurrently, the patient could be
concentrating the urine to 650 mOsm/kg H2O. Some patients
exhibit diagnostic characteristics suggesting an overlap of pre-
renal failure and ATN. In addition, all renal failure that we define
as ATN is not a model of proximal tubular injury. Rhabdomyolysis
is a cause of acute renal failure associated with very little direct
proximal tubular damage. Therefore, enzyme excretion might not
be increased. Undoubtedly tubular damage occurs while the
patient is still manifesting signs of pre-renal failure. In fact,
proximal tubular damage can contribute to renal vasoconstriction
via activation of tubuloglomerular feedback systems.
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